Investors

ImmuCell Corporation (Nasdaq: ICCC) has developed the First Defense® product line to deliver Immediate Immunity™ against E. coli, coronavirus, and rotavirus infections, the primary pathogens that cause scours (uncontrolled diarrhea), which is the leading disease risk to newborn dairy and beef calves. The Company estimates the cost of scours in the US to be over $700 million per year. The use of First Defense® immediately after birth enables producers to realize the genetic potential of their newborn livestock assets.

Investor Information

11-13-25 – ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025

Form 10Q for the period ended September 30, 2025

Recent News

02-18-26 ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025

01-08-26 ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025

01-07-26 ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus

View all press releases

Annual Meeting of Stockholders

Thursday, June 12, 2025 at 9:30 AM ET

Proxy Statement

Webcast

Our Core Technology

CEO Michael Brigham discusses ImmuCell’s core technology with Dr. Joseph H. Crabb former Chief Scientific Officer and VP of Product Development for ImmuCell and the developer of First Defense.

Download Transcript

Listen to Interview